Study for people with rheumatoid arthritis who tried standard medicines
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your diagnosis fits the 2010 criteria for rheumatoid arthritis (RA)
- You have tried standard DMARD tablets and they did not work (exact requirement depends on which study arm you match)
- For one part of the study: you have not already taken the newer biologic/targeted drugs (except possibly specific limits described by the study)
- You do not have reasons you cannot safely take these newer RA medicines (for example: serious active infection, untreated TB, certain cancers, or major organ problems)
- You can consent and complete study forms in English or French
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
This Phase 3 study compares two ways to treat active rheumatoid arthritis: a TNF-blocking biologic versus a targeted pill treatment. It may help people who are not doing well on (or cannot tolerate) certain biologic therapies to find a better, more practical option.
This Phase 4 study compares two treatment options for rheumatoid arthritis (RA): filgotinib or a TNF inhibitor (TNFi). It is designed for adults whose current “standard” RA tablets have not worked well or were not tolerated, to see which approach improves RA control.
This trial studies advanced medicines for rheumatoid arthritis (RA) in people whose RA is still active despite several standard treatments. It may help by testing whether a different advanced option can better control symptoms and joint inflammation.
This trial tests different targeted treatments for people with rheumatoid arthritis who have tried one or two biologic or targeted synthetic drugs but still have symptoms. You need to be taking a stable dose of methotrexate.
This study tests a new drug, RO7790121, for people with rheumatoid arthritis (RA) who have not gotten better with or could not tolerate common treatments like TNF inhibitors or JAK inhibitors. It aims to see if the drug is safe and can help reduce joint pain and swelling.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.